DBV Technologies, a biotech firm developing Viaskin, a dermal patch for peanut allergy tolerance, is rated a buy with a 24% upside to a $17 price target by FY 2027. The company is transitioning from research to commercial readiness, marked by increased sales and marketing spending and reduced research tax credits. A key catalyst is the planned Biologics License Application (BLA) submission in Q3 2026, which could lead to FDA approval and a commercial launch in 2027. However, risks include potential regulatory delays and uncertain market adoption, as seen with similar therapies like Palforzia.
Dogecoin (DOGE) is exhibiting a rare technical setup characterized by a prolonged sideways price movement around $0.07, an oversold RSI, and significant on-chain undervaluation. Large holders have recently accumulated over 430 million DOGE, reinforci...
Bitcoin exchange reserves are increasing, signaling potential selling pressure as more coins are ready to be sold. This rise coincides with a negative Coinbase Premium Index, indicating reduced buying interest from U.S. investors, a key market for Bi...
Bitcoin's price hovered near $63,069 following a 47% decline over the past year, with key support at $61,126 and resistance at $63,517. Michael Saylor highlighted that Strategy's STRC preferred stock, part of its digital credit products, returned 9% ...
Algorand's v5.0.0 upgrade has reached 90% node support and will activate soon after its cooldown period, marking the largest update since staking rewards launched. This upgrade introduces native Falcon-1024 post-quantum accounts, expanding quantum-re...
Since its 2021 reorganization, APA Corporation has prioritized reducing debt, cutting costs, and consolidating its portfolio rather than rapid production growth. Key moves include acquiring Callon Petroleum for $4.5 billion and increasing cost reduct...
